Dr Kirk Shepard Highlights the Results of Lenvatinib and Pembrolizumab QOLV in the Treatment of Advanced Endometrial Carcinoma

Findings showing similar health-related quality of life (HRQoL) scores in patients with advanced endometrial carcinoma undergoing combination therapy versus monochemotherapy could be significantly important, especially for disease that has not had a specifically approved treatment for 50 years, said Kirk Shepard. , MD, Chief Medical Officer, Senior Vice President and …

Read More »

Promising clinical activity observed in single agent and combination TG-1701 in CLL and other malignant B cell tumors

Encouraging clinical and pharmacodynamic activity was observed at all dose levels in patients with B-cell malignancies who received TG-1701, according to updated results from a phase 1/2 trial (NCT03671590) which were presented virtually at the ASCO 2021 annual meeting.1 The maximum tolerated dose of the BTK inhibitor was not reached …

Read More »

Treatment without HSCT and chemotherapy of Ph + ALL with Ponatinib / Blinatumomab leads to a CR rate of 100%

Combination therapy with ponatinib (Iclusig) and blinatumomab (Blincyto) produced a complete response in all patients with Philadelphia chromosome (Ph) positive acute lymphoid leukemia (ALL) who were treated in a phase 2 study ( NCT03263572), according to a presentation at the 2021 American Society of Clinical Oncology (ASCO) annual meeting.1 The …

Read More »

Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) annual meeting

PPRESS RELEASE Immunocore presentclinical The data further characterizing the overall survival benefit of tebentafuspin metastatic uveal melanoma at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Maryland, United States, June 04, 2021) Immunocore (Nasdaq: IMCR), an advanced biotechnology company pioneering the development …

Read More »

NSW spearheads key COVID-19 vaccine research

A leading group of experts in New South Wales will launch Australia’s first research to inform vaccine policy in the state and beyond. The Collaborative Research Group on Vaccines, Infections and Immunology (VIIM) will receive more than $ 4.5 million in NSW government funding over three years to study clinical …

Read More »